|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM378455605 |
| 003 |
DE-627 |
| 005 |
20250306175437.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
241003s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202412730
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1260.xml
|
| 035 |
|
|
|a (DE-627)NLM378455605
|
| 035 |
|
|
|a (NLM)39358936
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xing, Yumeng
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.11.2024
|
| 500 |
|
|
|a Date Revised 25.11.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Nanotechnology has proven its enormous application value in clinical practice. However, current research on nanomedicines mainly focuses on developing nanoparticles as delivery carriers to maximize the bioavailability of therapeutic agents, with little attention on exploring their potential to directly regulate physiological processes. In this study, inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, this work presents a lysosomal-targeting aggregated nanoparticle (LTANP) for cancer treatment. By rationally engineering surface composition, properties, and interparticle interactions, LTANP achieves efficient tumor accumulation and selective targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately inducing lysosomal membrane permeabilization (LMP) of cancer cells. Further analysis shows that nanoparticle aggregation-mediated LMP can effectively trigger immunogenic cell death (ICD) by impairing autophagy-lysosome pathway, evoking robust antitumor immune responses and reversing tumor immunogenicity from "cold" to "hot" in a melanoma model. Additionally, LTANP can combine with clinically approved programmed death ligand-1 (PD-L1) antibodies to further unleash T cell-mediated antitumor immunity, significantly enhancing antitumor performance, inhibiting tumor recurrence and metastasis. This work demonstrates the potential of rationally engineered nanostructures in directly combating cancer and provides novel insights for the development of advanced nanoparticle-based cancer treatment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a PD‐1/PD‐L1 blockade
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a immunogenic cell death
|
| 650 |
|
4 |
|a lysosomal membrane permeabilization
|
| 650 |
|
4 |
|a nanoparticle aggregation
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 700 |
1 |
|
|a Yang, Jianhui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peng, Ao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qian, Yujing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Pei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Qi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 47 vom: 01. Nov., Seite e2412730
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:47
|g day:01
|g month:11
|g pages:e2412730
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202412730
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 47
|b 01
|c 11
|h e2412730
|